CRISPR Therapeutics (NASDAQ: CRSP)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
CRISPR Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
CRISPR Therapeutics Company Info
CRISPR Therapeutics is a biotech company using gene therapy to try to correct genetic mutations to treat and cure diseases.
News & Analysis
2 Fantastic Growth Stocks to Buy Hand Over Fist
These stocks make great bargains today.
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Neither has performed well on the stock market this year.
3 No-Brainer Stocks to Buy Right Now for Less than $100
You can start with a small investment and win big over time.
CRISPR Therapeutics Stock: Bull vs. Bear
Here's the scoop on one of the most widely followed gene-editing stocks on the market.
Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time
Wood is going all in on gene editing.
This Cathie Wood Stock Is Set to Soar 100%, Says Wall Street
This Wood favorite is heading for a big moment.
2 Growth Stocks That Could Double Your Money, According to Wall Street
Find out why investment bank analysts are pounding the table on these stocks.
2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years
These two gene-editing stocks could be diamonds in the rough.
Valuation
Podcast Episodes
"The Era of the Gene-Edited Human Is Here"
An investor's look.
Breaking Down CRISPR Technology
What investors need to know.
Is Amarin's Fish Oil Pill on Track to Become a Blockbuster?
Plus, how gene-editing company CRISPR Therapeutics just took a big step forward.
Did China’s “Designer Babies” Just Open Pandora’s Box?
What will this mean for healthcare and for the future of society?
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.